Cargando…

Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes

Imeglimin is an orally administered first‐in‐class drug to treat type 2 diabetes mellitus (T2DM) and is mainly excreted unchanged by the kidneys. The present study aimed to define the pharmacokinetic (PK) characteristics of imeglimin using population PK analysis and to determine the optimal dosing r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomita, Yoshiko, Hansson, Emma, Mazuir, Florent, Wellhagen, Gustaf J, Ooi, Qing Xi, Mezzalana, Enrica, Kitamura, Atsushi, Nemoto, Daisuke, Bolze, Sébastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010270/ https://www.ncbi.nlm.nih.gov/pubmed/34962074 http://dx.doi.org/10.1111/cts.13221

Ejemplares similares

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
por: Theurey, Pierre, et al.
Publicado: (2022)

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action
por: Hallakou-Bozec, Sophie, et al.
Publicado: (2021)

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity
por: Theurey, Pierre, et al.
Publicado: (2022)

Stimulatory effect of imeglimin on incretin secretion
por: Yingyue, Quan, et al.
Publicado: (2023)

Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
por: Detaille, D, et al.
Publicado: (2016)

Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
por: Yaribeygi, Habib, et al.
Publicado: (2020)

Current understanding of imeglimin action on pancreatic β‐cells: Involvement of mitochondria and endoplasmic reticulum homeostasis
por: Fauzi, Muhammad, et al.
Publicado: (2022)

Effects of the anti-diabetic imeglimin in hyperglycemic mice with septic shock
por: Wagner, F, et al.
Publicado: (2012)

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells
por: Vial, Guillaume, et al.
Publicado: (2021)

Imeglimin‐mediated glycemic control in maternally inherited deafness and diabetes
por: Ishibashi, Ryoichi, et al.
Publicado: (2023)

Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes
por: Hozumi, Kaori, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes
por: Vuylsteke, Valerie, et al.
Publicado: (2015)

Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Development of Imeglimin Electrospun Nanofibers as a Potential Buccal Antidiabetic Therapeutic Approach
por: Alamer, Ali A., et al.
Publicado: (2023)

Letter to the Editor: Can Imeglimin Improve the Systolic Time Intervals in Diabetes Mellitus?
por: Nishikawa, Tomoaki, et al.
Publicado: (2023)

Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study
por: Uchida, Taisuke, et al.
Publicado: (2023)

Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes
por: Wellhagen, Gustaf J., et al.
Publicado: (2018)

A Bounded Integer Model for Rating and Composite Scale Data
por: Wellhagen, Gustaf J., et al.
Publicado: (2019)

Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data
por: Wellhagen, Gustaf J., et al.
Publicado: (2020)

A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine
por: Kanacher, Tobias, et al.
Publicado: (2020)

Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes
por: Yamagishi, Hirofumi, et al.
Publicado: (2023)

A Response to Letter to the Editor: Can Imeglimin Improve the Systolic Time Intervals in Diabetes Mellitus?
por: Uchida, Taisuke, et al.
Publicado: (2023)

Pharmacokinetic Profiles of Ticagrelor Orodispersible Tablets in Healthy Western and Japanese Subjects
por: Teng, Renli, et al.
Publicado: (2017)

A Bayesian Approach for Population Pharmacokinetic Modeling of Alcohol in Japanese Individuals
por: Nemoto, Asuka, et al.
Publicado: (2017)

Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response
por: Wellhagen, Gustaf J., et al.
Publicado: (2020)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome
por: Lachaux, Marianne, et al.
Publicado: (2020)

A novel mechanism of imeglimin‐mediated insulin secretion via the cADPR‐TRP channel pathway
por: Funazaki, Shunsuke, et al.
Publicado: (2021)

An Item Response Theory–Informed Strategy to Model Total Score Data from Composite Scales
por: Wellhagen, Gustaf J., et al.
Publicado: (2021)

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of two randomized, placebo‐controlled trials
por: Hagi, Katsuhiko, et al.
Publicado: (2023)

Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules
por: Sanada, Junpei, et al.
Publicado: (2022)

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2015)

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects
por: Tompson, Debra J., et al.
Publicado: (2020)

Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta‐analysis of randomized controlled trials
por: Hagi, Katsuhiko, et al.
Publicado: (2023)

The Effects of Imeglimin on the Daily Glycemic Profile Evaluated by Intermittently Scanned Continuous Glucose Monitoring: Retrospective, Single-Center, Observational Study
por: Oda, Tomoyasu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4i2dfn6d0a1qg73avaqscetfsb